Erratum {#Sec1}
=======

Upon Publication of the original article \[[@CR1]\] several discrepancies were highlighted in the following sections; Results, Table 1, Table [2](#Tab1){ref-type="table"} and Fig. [3](#Fig1){ref-type="fig"}. These errors have since been acknowledged and corrected in this erratum

**The first sentence in the subsection "Baseline characteristics" originally read:** Patients' baseline and demographic characteristics are shown in Table 1 (mITT population).

**This should read:** Patients' baseline and demographic characteristics are shown in Table 1.

**The header of Table 1 read:** Baseline demographics (mITT population)

**This should read as:** Baseline demographics (ITT population)

It was noticed that Table [2](#Tab1){ref-type="table"} contained an error. In Table [2](#Tab1){ref-type="table"}, data row 2, the footnote symbol 'c' was erroneously included in the third column. The footnote symbol 'c 'should be placed in the second column in this row. The corrected Table [2](#Tab1){ref-type="table"} is shown below.Table 2FEV~1~ AUC~0--12~ at Day 7: GFF MDI 72/9.6 μg and 36/9.6 μg comparisons (mITT population)LSM treatment differences for GFF MDI in FEV~1~ AUC~0--12~ at Day 7GFF MDIGP MDI 36 μgOpen-label tiotropium 18 μgFF MDIPlacebo MDIOpen-label FF^a^ DPI 12 μgComparator72/9.6 μg36/9.6 μg9.6 μg7.2 μgGFF MDI 72/9.6 μg LSM^b^ difference (SE), L 95% CINA0.008 (0.0236)--0.039, 0.054^c^0.109 (0.0250)^†^0.059, 0.1580.103 (0.0216)^†^0.060, 0.1450.116 (0.0245)^†^0.068, 0.1650.124 (0.0237)^†^0.078, 0.1710.298 (0.0261)^†^0.247, 0.3490.101 (0.0241)^†^0.053, 0.148GFF MDI 36/9.6 μg LSM^b^ difference (SE), L 95% CISee aboveNA0.101 (0.0245)^†^0.053, 0.1490.095 (0.0213)^†^0.053, 0.1370.109 (0.0242)^†^0.061, 0.1560.116 (0.0236)^†^0.070, 0.1630.290 (0.0261)^†^0.239, 0.3420.093 (0.0241)^\*\*\*^0.045, 0.140^\*\*\*^ *p \<* 0.001; ^†^ *p \<* 0.0001^a^Foradil® Aerolizer®; ^b^LSM allows for any imbalances in baseline covariates that relate to responses to be adjusted for in order to avoid bias in treatment effect estimates; ^c^non-inferiority comparisonCI, confidence interval; DPI, dry powder inhaler; FEV~1~ AUC~0--12~, forced expiratory volume in 1 s area under the curve from 0 to 12 h post-dose; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; LSM, least squares mean; MDI, metered dose inhaler; mITT, modified intent-to-treat; NA, not available; SE, standard error

It was noticed that in Fig. [3b](#Fig1){ref-type="fig"}, the error bar on the 4th data point (AUC~inf~) was incorrectly given. The error bar on the 4th data point (AUCinf) should range from 74.88, to 103.28 The corrected Fig. [3b](#Fig1){ref-type="fig"} is shown below.Fig. 3Ratio of geometric LSMs and 90% CIs. (**a**) GFF MDI 36/9.6 μg versus GP MDI 36 μg (**b**) GFF MDI 36/9.6 μg versus FF MDI 9.6 μg (**c**) FF MDI 9.6 μg versus FF DPI (PK-mITT population). ^a^LSM allows for any imbalances in baseline covariates that relate to responses to be adjusted for in order to avoid bias in treatment effect estimates. ^b^Foradil® Aerolizer®^.^AUC~0--inf~, area under the curve from time 0 to infinity; AUC~0--12~, area under the curve from 0 to 12 h post-dose; CI, confidence interval; C~max~, maximum observed plasma concentration; DPI, dry powder inhaler; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; LSM, least squares mean; MDI, metered dose inhaler; PK-mITT, pharmacokinetic modified intent-to-treat

These corrections do not change the conclusions of the article.

The online version of the original article can be found under doi:10.1186/s12931-016-0491-8
